RecruitingNCT07429851

CompArative Analysis Between, Thymic, pulmonaRy and Pancreatic Well Differentiated High Grade Neuroendocrine Tumors

CLINical, Pathological and outcomE compArative Analysis Between, Thymic, pulmonaRy and Pancreatic Well Differentiated High Grade Neuroendocrine Tumors: a Retrospective Observational Study


Sponsor

European Institute of Oncology

Enrollment

34 participants

Start Date

Jan 1, 2026

Study Type

OBSERVATIONAL

Conditions

Summary

The study involves the enrollment of 34 patients diagnosed with advanced thymic, pulmonary and duodeno-pancreatic well-differentiated high grade neuroendocrine tumors (Ki-67 \> 20%). The objective of this retrospective single-centre translational study will be to explore whether patients differ clinically in terms of diagnosis and treatment management. Currently, well differentiated high grade pulmonary NETs are managed using extrapolated algorithms from duodeno-pancreatic NETs, underlining a significant unmet clinical need. This is likely due to the rarity, uncertain pathological and molecular classification, and heterogeneous clinical course of well differentiated high grade pulmonary NETs. In this study a retrospective data-base of pulmonary, thymic and duodeno-pancreatic NETs with Ki-67 \> 20% will be created in order to analyze diagnostic and therapeutic pathways, clinical outcomes, imaging, disease evolution and molecular profiling. This study will adopt a hypothesis-generating approach to explore whether patients in these distinct groups differ clinically in terms of diagnosis and treatment management.


Eligibility

Plain Language Summary

Simplified for easier understanding

This study is looking at a rare type of aggressive neuroendocrine tumour (a cancer that starts in hormone-producing cells) that arises in the thymus, lungs, or pancreas/duodenum, and has a high rate of cell division. Researchers are comparing clinical and molecular features across these different tumour locations to understand how they differ and how best to treat them. **You may be eligible if...** - You have a confirmed diagnosis of a well-differentiated high-grade neuroendocrine tumour (Ki-67 > 20%) reviewed by a specialist pathologist - Your tumour originates in the thymus, lung, or duodenum/pancreas - You have advanced disease - Adequate clinical records about your diagnosis and treatment are available **You may NOT be eligible if...** - Your diagnosis is a poorly differentiated neuroendocrine carcinoma (NEC) - Your tumour is a low or intermediate grade neuroendocrine tumour (G1/G2) - Your tumour has a Ki-67 below 20% - Your tumour originates from a site other than thymus, lung, or pancreas - Your records or tissue samples are incomplete Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

European Institute of Oncology

Milan, Italy, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07429851